Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00599274 · ClinicalTrials.gov registry record
Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 136
- Enrollment target
NCT00599274: Completed study, sponsored by Biogen.
NCT00599274 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 136 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00599274 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 136 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if weekly Avonex works as well as three times a week Rebif in subjects with relapsing multiple sclerosis.
Interventions
- DRUG Interferon beta-1a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2002-08 |
| Est. Completion | 2003-05 |
What the finished NCT00599274 record still lists
NCT00599274 is an observational study that tracks outcomes without assigning an intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Interferon beta-1a is the first listed.
NCT00599274 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00599274 about?
NCT00599274 is a clinical study titled "Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis". The purpose of this study is to find out if weekly Avonex works as well as three times a week Rebif in subjects with relapsing multiple sclerosis.
What is the current status of trial NCT00599274?
This trial is currently completed. The enrollment target is 136 participants. The study started on 2002-08. Estimated completion is 2003-05.
What interventions are being tested in trial NCT00599274?
The interventions under investigation include: Interferon beta-1a (DRUG).
Who is sponsoring clinical trial NCT00599274?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia